AAA September 2017 – Page 4

SpringWorks moves to $103m series A

SpringWorks Therapeutics, a US-based drug developer focused on currently incurable diseases, launched yesterday with $103m in series A funding from a consortium that featured pharmaceutical firm Pfizer. The round also included medical research charity LifeArc as well as investment firm Orbimed and private equity firm Bain Capital, which took part through its Life Sciences fund… Continue reading SpringWorks moves to $103m series A